Latest Conference Articles

The first phase 3 results from the CARTITUDE-4 trial of ciltacabtagene autoleucel (cilta-cel) vs standard of care in lenalidomide-refractory multiple myeloma (MM) demonstrated the former’s convincing superiority in several key outcomes.

Results from the ASPEN and ALPINE trials of zanubrutinib showed greater improvements in quality of life (QOL) vs ibrutinib.

Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, shared her thoughts on the current research regarding Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL-2) inhibitors in chronic lymphocytic leukemia (CLL) and what providers should keep in mind before prescribing them.

MD Anderson Cancer Center's Hans Lee, MD, shared considerations for possible infection risk associated with bispecific therapies used to treat relapsed/refractory multiple myeloma (MM) at the European Hematology Association 2023 Congress

An analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) deficiency mutations showed that patients with BRCA mutations had poor outcomes compared with those without BRCA mutations and those with non-BRCA HRR mutations.

A friendly debate held at the European Hematology Association 2023 Congress focused on the potential for real-world data to improve the generalizability of clinical trial results but also acknowledged the limitations and current challenges with these data.

If payers can agree on consensus criteria to improve care quality or costs, that will help physicians remember and try to be compliant, said Samyukta Mullangi, MD, MBA, incoming medical director at Thyme Care.

The use of immune therapies for hematological malignancies is expanding beyond chimeric antigen receptor (CAR) T-cell therapies in the traditional lymphoid disease states, but the impact on patient quality of life must remain top of mind, according to speakers at the European Hematology Association 2023 Congress.

Watch and see what Michael Shapiro, DO, FASPC, president-elect of the American Society for Preventive Cardiology, wants you to know about this year's ASPC Congress on CVD Prevention.

Children with narcolepsy often have disrupted nighttime sleep (DNS), which could lead to other effects, such as memory issues.

In this interview with The American Journal of Managed Care®, Symielle A. Gaston, PhD, MPH, of the National Institute of Environmental Health Sciences (NIEHS) of the National Institutes of Health, explores the relationship between sleep health and outcomes disparities among patients of various races and ethnicities.

Panelists at SLEEP 2023 presented preliminary data on how sleep interventions could close the gap in treating Black children and families in sleep health.

Posters presented at the SLEEP 2023 conference showed that transition between medications was easy but 1 medication felt more effective to patients.

Targeting insomnia with cognitive behavior therapy is almost like a frontline therapy, because by doing so, you’re able to improve a whole host of other symptoms that would coexist with insomnia, explained Sheila Garland, PhD, MSc, Memorial University in Newfoundland, Canada.

A panel at SLEEP 2023 discussed the ways that long COVID-19 has affected numerous areas of sleep health.

Research is finding that there is an intricate connection between sleep and inflammation, such that lack of sleep can increase inflammation, noted Andrew McHill, PhD, an assistant professor at Oregon Health and Science University.

Robert Sidbury, MD, MPH, professor of pediatrics at Seattle Children's Hospital, discusses best practices that physicians and parents of infants with atopic dermatitis (AD) can do to help manage flare- ups, as well as barriers to care, which he presented at the Revolutionizing Atopic Dermatitis conference.

Dayna Johnson, PhD, MPH, MSW, MS, the Rollins School of Public Health at Emory University, discusses principal findings from the analysis of a 35-day sleep intervention study that utilized a mobile mindfulness app to manage stress and anxiety combined with healthy sleep practices.

Posters presented at SLEEP 2023 estimated the prevalence of idiopathic hypersomnia as well as incidence of comorbidities.

Presenters at SLEEP 2023 revealed research that linked childhood sleep patterns to weight in young children.

Travis Brewer, vice president of payer relations at Texas Oncology, discusses the importance of oncologists’ collaboration with payers to improve value-based care.

It’s important to consider the social context, the social ecology, and the family environment when investigating behavioral sleep problems among children and adults, noted Arielle Williamson, PhD, DBSM, Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine.

While efforts are underway to improve access to cutting-edge oncology clinical trials for underserved patients, more work is needed to get the job done, said a panel of experts at the 2023 American Society of Clinical Oncology Annual Meeting.

The session, “Payment Reform: Lessons Learned from the Oncology Care Model (OCM) and Implications for the Enhancing Oncology Model (EOM)," comes less than a month before the EOM is set to begin.

Judite Blanc, PhD, is lead author on the abstract, “Social Determinants of Sleep Disorders Among Multiethnic Americans in the NIH All of Us Research Program,” which was presented today at SLEEP 2023.

Jason Westin, MD, MS, FACP, director of the Lymphoma Clinical Research Program at the University of Texas MD Anderson Cancer Center, gave insight the ZUMA-7 trial of axicabtagene ciloleucel (axi-cel) in relapsed or refractory large B-cell lymphoma (R/R LBCL) and the study's implications in the broader LBCL landscape.

Judy Wang, MD, medical oncologist and clinical trials investigator at Sarah Cannon Research Institute at Florida Cancer Specialists & Research Institute, discussed the mechanism of action and rationale for studying CLN-619, an anti-MICA/B antibody, with and without pembrolizumab in patients with solid tumors.

In early findings, the antibody drug conjugate created strong responses in multiple tumor types where patients have unmet need.

Bhagirathbhai R. Dholaria, MD, assistant professor of medicine in the Department of Hematology-Oncology at Vanderbilt University Medical Center, discussed findings from the phase 2 TRiMM-2 trial of talquetamab plus daratumumab in multiple myeloma.

Barb Kunz, MS, LCGC, senior genetic counselor at the US Oncology Network, shared insight on a study of social determinants of health in the context of germline genetic testing for triple-negative breast cancer (TNBC) in the community oncology setting.